Not impressed with Roth Capital as a general rule, but, if accurate then this post (#msg-130702786) does foment an intriguing possibility of "boing-ability" re: the part where it says-
"Conatus price target raised to $12 from $4 at Roth Capital ...following discussions with management, 2016 results, assessment of the competitive cirrhosis space, and clarity from the Novartis (NVS) deal."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.